Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery

21 May 2021

Abstract excerpt

Cell division cycle 7 (CDC7), a serine/threonine kinase, plays important roles in DNA replication. We developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. This study aimed to identify the potential combination partners of TAK-931 for guiding its clinical development strategies. Unbiased high-throughput chemical screening revealed that the highest synergistic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34020950
DOI: 10.1126/sciadv.abf0197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoveryPMID 34020950Read ↗

CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockadeSemantic proximity Read ↗

Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer TherapySemantic proximity Read ↗

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read ↗

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferationSemantic proximity Read ↗

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell LymphomasSemantic proximity Read ↗

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read ↗

Thymidine phosphorylase associates with DNA damage repair to facilitate stemness maintenance, chemoresistance, and immunosuppression in pan-cancerSemantic proximity Read ↗

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)Semantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

Dual genome-wide CRISPR knockout and CRISPR activation screens identify common mechanisms that regulate the resistance to multiple ATR inhibitorsSemantic proximity Read ↗

REV7 in Cancer Biology and ManagementSemantic proximity Read ↗

Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.